Proteasome Inhibitors in Cancer Therapy by Julian AdamsProteasome Inhibitors in Cancer Therapy by Julian Adams

Proteasome Inhibitors in Cancer Therapy

EditorJulian Adams

Paperback | November 19, 2010

Pricing and Purchase Info

$316.50 online 
$336.95 list price save 6%
Earn 1583 plum® points

In stock online

Ships free on orders over $25

Not available in stores


A panel of leading academic and pharmaceutical investigators takes stock of the remarkable work that has been accomplished to date with proteasome inhibitors in cancer, and examines emerging therapeutic possibilities. The topics range from a discussion of the chemistry and cell biology of the proteasome and the rationale for proteasome inhibitors in cancer to a review of current clinical trials underway. The discussion of rationales for testing proteasome inhibitors in cancer models covers the role of the proteasome in NF-kB activation, the combining of conventional chemotherapy and radiation with proteasome inhibition, notably PS-341, new proteasome methods of inhibiting viral maturation, and the role of protesome inhibition in the treatment of AIDS. The authors also document the development of bortezomib (VelcadeT) in Phase I clinical trials and in a multicentered Phase II clinical trials in patients with relapsed and refractory myeloma.
Title:Proteasome Inhibitors in Cancer TherapyFormat:PaperbackDimensions:328 pagesPublished:November 19, 2010Publisher:Humana PressLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:1617374520

ISBN - 13:9781617374524

Look for similar items by category:


Table of Contents

I. Cancer Drug DevelopmentCancer Drug Development: Challenges in a Competitive MarketBarry Greene and Michael KauffmanII. Chemistry and Cell Biology of the ProteasomeIntroduction to the Proteasome and Its Inhibitors: Biochemistry and Cell BiologyAlfred L. GoldbergStructures of the Yeast Proteasome Core Particle in Complex with InhibitorsMichael Groll and Robert HuberNatural Product and Synthetic Proteasome InhibitorsKyung Bo Kim and Craig M. CrewsOther Proteasome InhibitorsCarlos García-EcheverríaThe Proteasome in Cell-Cycle RegulationJulian AdamsProteasome Inhibition and ApoptosisSimon A. Williams and David J. McConkeyThe Proteasome and the COMPARE AlgorithmSusan L. Holbeck and Edward A. SausvilleIII. Rationale for Proteasome Inhibitors in CancerThe Proteasome in Cancer Biology and TherapyFrank Pajonk and William H. McBrideRadiosensitization and Proteasome InhibitionCarter Van Waes, John B. Sunwoo, William DeGraff, and James B. MitchellProteasome-Dependent Regulation of NF-kB Activation: Molecular Targeting of Chemotherapy ResistanceJames C. Cusack, Jr.Bortezomib with TaxanesLeonard Liebes, Bruce Ng, Yi-He Ling, and Roman Perez-SolerProteasome Inhibitor Therapy in a Brain Tumor ModelJeffrey J. Olson, Geoffrey Bowers, and Zhaobin ZhangAnthracyclines and BortezomibRobert Z. OrlowskiTNF-Related Apoptosis-Inducing Ligand (TRAIL): Combination with Proteasome Inhibition For Anticancer Therapy?Thomas J. SayersRationale for Combining the Proteasome Inhibitor Bortezomib with CisplatinEdward G. Mimnaugh and Leonard M. NeckersThe Effects of the HIV-1 Protease Inhibitor Ritonavir on Proteasome Activity and Antigen PresentationMarcus Groettrup, Rita de Giuli, and Gunter SchmidtkeFunction(s) of the Ubiquitin-Proteasome System in Retrovirus BuddingUlrich SchubertIV. Clinical TrialsPreclinical Development of Bortezomib (VELCADET): Rationale for Clinical StudiesJulian Adams, Peter J. Elliott, and Page BouchardPhase I Trials: Bortezomib Alone and in Combination With Standard ChemotherapiesDixie-Lee W. Esseltine and David P. SchenkeinClinical Molecular Diagnostics for Proteasome Inhibitors in Cancer TherapyJeffrey S. Ross, Gerald P. Linette, Geoffrey S. Ginsburg, William Trepicchio, Oscar Kashala, Rebecca Mosher, Jeffrey Brown, George Mulligan, Jim Deeds, and James StecPhase II Trials of Bortezomib for the Treatment of Multiple MyelomaKenneth C. AndersonIndex

Editorial Reviews

"Authoritative and illuminating...." - Tumori